The London New Drugs Group Terms of Reference, September 2011 Purpose and function of the London New Drugs Group The purpose of the London New Group (LNDG) is to act as an expert collaborative advisory body to support commissioners and providers make rational decisions regarding new medicines and strategic medicines issues. The group focusses particularly on issues where significant clinical or financial impact is envisaged for a given medicine. The group works to ensure evidence of efficacy, safety, and cost-effectiveness is reflected in evaluations and as such the outputs support the QIPP agenda. The LNDG considers medicines only where they will not be or have not yet been considered by NICE; in addition, LNDG seeks not to repeat the work of other NHS medicines review bodies unless there are specific local circumstances warranting action. The LNDG does not consider orphan, ultra-orphan, or unlicensed medicines routinely unless there are specific circumstances warranting action. LNDG undertakes the following specific functions: Early identification of new medicines and strategic medicines issues A continual programme of horizon scanning using NHS resources identifies new medicines with potential implications. In addition, other strategic medicines issues are identified through the group’s membership and networks. Publication of detailed timely reviews according to a defined work programme and format A process of triage seeks to ensure detailed review of medicines only where there is a definite need. The process involves group members and external stakeholders considering identified new medicines and issues; takes account of the work of other national and regional review bodies; and ultimately seeks to ensure providers and commissioners have access to detailed peer-reviewed advice on given medicines in a timely manner. Publication of reviews that consider the evidence-base, expert opinion, and provider and commissioner views The networks of the LNDG ensure a range of views from stakeholders form part of the process of review production, thus ensuring the work is grounded in the reality of the NHS in London. Publication of reviews that recommend particular courses of action where appropriate
The London New Drugs Group Terms of Reference, September 2011 Purpose and function of the London New Drugs Group The purpose of the London New Group (LNDG) is to act as an expert collaborative advisory body to support commissioners and providers make rational decisions regarding new medicines and strategic medicines issues. The group focusses particularly on issues where significant clinical or financial impact is envisaged for a given medicine. The group works to ensure evidence of efficacy, safety, and cost-effectiveness is reflected in evaluations and as such the outputs support the QIPP agenda. The LNDG considers medicines only where they will not be or have not yet been considered by NICE; in addition, LNDG seeks not to repeat the work of other NHS medicines review bodies unless there are specific local circumstances warranting action. The LNDG does not consider orphan, ultra-orphan, or unlicensed medicines routinely unless there are specific circumstances warranting action. LNDG undertakes the following specific functions: Early identification of new medicines and strategic medicines issues A continual programme of horizon scanning using NHS resources identifies new medicines with potential implications. In addition, other strategic medicines issues are identified through the group’s membership and networks. Publication of detailed timely reviews according to a defined work programme and format A process of triage seeks to ensure detailed review of medicines only where there is a definite need. The process involves group members and external stakeholders considering identified new medicines and issues; takes account of the work of other national and regional review bodies; and ultimately seeks to ensure providers and commissioners have access to detailed peer-reviewed advice on given medicines in a timely manner. Publication of reviews that consider the evidence-base, expert opinion, and provider and commissioner views The networks of the LNDG ensure a range of views from stakeholders form part of the process of review production, thus ensuring the work is grounded in the reality of the NHS in London. Publication of reviews that recommend particular courses of action where appropriate
Terms%20of%20Reference%20Sept%202011b.docx